Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APRES-AKI
NCT07734636Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in acute kidney injury (AKI) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Feasibility- RASi use separation up to 90 days. Started Sep 2026; status: recruiting.
02
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07734636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734636.